- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07854730
Effect of Ventilator Hyperinflation Combined With Body Positioning on ABG in VAP
Effect of Ventilator Hyperinflation Combined With Body Positioning on Arterial Blood Gases In Patients With Ventilator-Associated Pneumonia : A Randomized Controlled Trial
This study aims to evaluate the effect of ventilator hyperinflation combined with body positioning on arterial blood gases in patients with ventilator-associated pneumonia. Forty-two mechanically ventilated patients will be randomly assigned into two groups receiving the intervention in either supine or lateral decubitus positions. Arterial blood gases will be assessed over a 6-day intervention period. The findings are expected to provide evidence regarding the optimal positioning strategy to enhance the effectiveness of ventilator hyperinflation in improving gas exchange in critically ill patients.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Cairo, Egypte, 11571
- Recrutement
- Mohamed Saied Zidan
-
Contact:
- Mohamed S Zidan, phd
- Numéro de téléphone: 01016469801
- E-mail: drmohzidan2015@gmail.com
-
Contact:
- Mohamed S Zidan
- Numéro de téléphone: 01016469801
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Mechanically ventilated patients ≥ 48 hours
- Diagnosed with VAP (clinical + chest X-ray)
- Age: 40-60 years
- Hemodynamically stable
- Unilateral lung involvement
Exclusion Criteria:
- Bilateral lung disease
- Unstable cardiovascular conditions
- Contraindications to positioning
- Re-intubation cases
- Presence of pneumothorax or air leak
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: La prévention
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: ventilator hyperinflation from lateral decubitus position
This group will receive Ventilator hyperinflation in lateral decubitus position (affected lung uppermost) and Conventional respiratory physiotherapy |
a therapeutic technique used by clinicians (Manual or Ventilator Hyperinflation) to clear secretions and recruit collapsed lung tissue, or an inadvertent complic |
|
Expérimental: Manual hyperinflation for Lateral decubitus position
This group will receive manual hyperinflation in Lateral decubitus position and Conventional respiratory physiotherapy |
a respiratory therapy technique that uses a manual resuscitation bag to deliver larger-than-normal, controlled breaths to clear airway secretions and reopen collapsed lung areas |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
PaCO2
Délai: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
partial pressure of carbon dioxide in arterial blood, measuring how effectively the lungs eliminate carbon dioxide |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
|
PaO2
Délai: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
partial pressure of oxygen dissolved in arterial blood plasma, measured through an Arterial Blood Gas (ABG) test. |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
|
SaO2
Délai: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
the percentage of oxygen-saturated hemoglobin relative to total hemoglobin in arterial blood, typically measured via an invasive arterial blood gas (ABG) analysis with normal values ranging from 95% to 99% |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
|
PaO2/FiO2 (P/F)
Délai: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
a clinical metric used to evaluate oxygenation efficiency and diagnose the severity of acute hypoxemic respiratory failure or Acute Respiratory Distress Syndrome (ARDS). |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Pulmonary compliance
Délai: Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
the change in lung volume divided by the change in pressure (Δ V / Δ P). Higher compliance means the lungs stretch easily; lower compliance means they are stiff and harder to inflate |
Will be assessed at baseline (day 1) pre the intervention of the 1st session and (day 6) post the intervention of the 12th session.
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB # 14/5/2025-2026
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .